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Reversed Alterations of Hippocampal
Parvalbumin and Protein Kinase C-y
Immunoreactivit After Stroke in Spontaneously
Hypertensive Stroke-Prone Rats
G.I. De Jong, PhD; E.A. Van der Zee, PhD; B. Bohus, MD, PhD; P.G.M. Luiten, PhD
Background and Purpose: Aging spontaneously hypertensive stroke-prone rats (SHR-SP) were previously
shown to develop neocortical strokes. Because the hippocampal CA1 is selectively vulnerable to abnormal
brain perfusion, the neuropathological effects of spontaneous strokes were investigated on specific
neurochemical alterations in two major cell types of the hippocampal CA1 in SHR-SP.
Methods: The immunoreactivity for the y-isoform of protein kinase C (in pyramidal cells) and
parvalbumin (in interneurons) was determined in the hippocampal CA1 by applying monoclonal
antibodies. Because chronic treatment with the calcium antagonist nimodipine prevents the development
of strokes in SHR-SP, we compared SHR-SP (stroke) with age-matched nimodipine-treated rats
(nonstroke).
Results: After stroke in control animals, we observed a strikingly enhanced immunoreactivity for protein
kinase C-y in CA1 pyramidal cells compared with nimodipine-treated rats, which can be interpreted as
the result of an increased activation of these cells. The pathological increase of protein kinase C-y
immunoreactivity was accompanied by a reduced parvalbuminergic innervation of these pyramidal cells
in symptomatic SHR-SP.
Conclusions: Because parvalbumin is present in a subset of GABAergic inhibitory interneurons, these
data suggest that increased activity of CAl pyramidal cells after spontaneous stroke may partially be
related to a decreased inhibitory input on these cells. (Stroke. 1993;24:2082-2086.)
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Es ssential hypertension is a common phenomenon
in the elderly' and is considered a major risk
factor for the occurrence of stroke.2 The spon-
taneously hypertensive stroke-prone rat (SHR-SP)
strain, obtained by selective breeding of SHR,3 has
proven to be a valuable pathogenetic model for the
study of experimental hypertension and stroke.4 At the
age of 43 to 52 weeks SHR-SP develop cerebral hem-
orrhages and infarcts (strokes), which shortens the
mean life span of SHR-SP compared with normotensive
Wistar rats.56 Cerebrovascular lesions in SHR-SP pre-
dominantly occur in the neocortex at the boundaries
between the middle cerebral artery and the anterior and
posterior cerebral artery.3
Most studies on neurochemical alterations after ab-
normal perfusion of the brain are based on experimen-
tally induced ischemia (for review, see Reference 7).
Ischemia gives rise to neuronal damage, with the pyra-
midal cells in the hippocampal CA1 being one of the
most vulnerable cell types in the central nervous sys-
tem.8 The massive release of the excitatory amino acid
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glutamate in the hippocampus during cerebral ischemia is
a key factor in ischemia-induced neuronal damage and cell
death.9 Enhancement of the activity and/or translocation
of the enzyme protein kinase C (PKC) might also play an
important role in postischemic alteration of neuronal
functioning in the hippocampus.10-12 More recently some
attention has also been directed to possible alterations in
postsynaptic inhibitory processes after ischemia.13
Much less is known about neurochemical alterations
after spontaneous strokes. We previously showed that
chronic application of the calcium entry blocker nimo-
dipine starting at the age of 46 weeks prevented the
occurrence of stroke in SHR-SP5,6 without reducing the
(high) systolic blood pressure.5 Comparison of age-
matched SHR-SP with (nontreated) and without (nimo-
dipine-treated) spontaneous strokes enabled us to reveal
neurochemical alterations that occur after spontaneous
strokes. In the present study we examined the effect of
stroke in aging SHR-SP on the expression of PKCy and
the calcium binding protein parvalbumin (PV) in dorsal
hippocampal pyramidal and nonpyramidal inhibitory in-
terneurons, respectively.
Materials and Methods
The current investigation is based on observations in
22 male SHR-SP (breeder: M0llegaard, Sk0nev0d, Den-
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mark). At the age of 46 weeks the animals were divided
into two groups (both n= 11), one of which received
standard food pellets (SP-placebo). The other group
(SP-nimo) received identical food pellets to which 860
ppm nimodipine (Bayer AG, Leverkussen, Germany)
was added. Treatment was carried out for a period of 10
weeks (from 46 to 56 weeks), after which the experiment
had to be terminated because 4 of 11 placebo animals
had died as a result of stroke. The remaining 7 SP-
placebo and 7 randomly selected SP-nimo animals were
deeply anesthetized with 60 mg/kg IP sodium pentobar-
bital. Brains were fixed by means of transcardial perfu-
sion with 400 mL fixative containing 3% paraformalde-
hyde, 0.05% glutaraldehyde, and 2% picric acid in 0.1
mol/L phosphate buffer (PB) at pH 7.4. The brains were
removed, and the brain weight of each animal was
determined. The brains were stored overnight at 4°C in
30% buffered sucrose for cryoprotection and subse-
quently cut on a cryostat microtome to 20-,m coronal
sections.
For immunocytochemical stainings of PV and PKCy
we used previously described protocols.14'5 In short,
sections from SP-placebo and SP-nimo animals were
pooled and incubated overnight at 4°C in phosphate-
buffered saline (PBS) containing either monoclonal
mouse anti-PV immunoglobulin (Ig) G (Sigma Chemi-
cal Co, St Louis, Mo; diluted at 1:2000) or mouse
anti-PKCy IgG (36G9, monoclonal antibody raised
against purified bovine PKCy,16 kindly donated by Dr S.
Cazaubon, Paris, France; diluted at 1:200). Subse-
quently, the sections were exposed to biotinylated sheep
anti-mouse IgG (Amersham, 1:200 in PBS, 2 hours at
room temperature) and streptavidin-horseradish perox-
idase (Zymed, 1:200 in PBS, 2 hours at room tempera-
ture). In both immunostainings, the sections were rinsed
at least four times between all incubation steps in PBS,
to which in the case of PV 0.5% Triton X-100 was
added. Immunolabeling was visualized by 0.03% diami-
nobenzidine and 0.01% H202. Standard control experi-
ments were performed by omission of the primary
antibodies, yielding absence of any detectable immuno-
labeling. The brain weight data were tested by analysis
of variance (ANOVA), with statistical significance de-
fined as P<.05.
Results
During the treatment period (46 to 56 weeks of age),
all SP-placebo rats showed neurological symptoms of
strokes, such as hyperirritability, motion disturbances,
and behavioral depression.3 After light microscopic
analysis of the brain sections, neocortical hemorrhages
and infarcts were encountered in all SP-placebo animals
(Table). The SP-nimo animals did not show any clear
neurological symptoms of stroke. Microscopic evalua-
tion, however, revealed signs of a small stroke in the
neocortex of two of seven SP-nimo rats (Table).
The occurrence of stroke in SP-placebo rats was
accompanied by severe brain edema formation. The
brains of all SP-placebo rats were macroscopically swol-
len, and the brain weight was extremely high (Table).
No signs of brain edema were observed in the SP-nimo
group, and the mean brain weight of these animals was
normal (Table) and in the same range as that of
normotensive controls.5 Moreover, the brain weight of
Number of Rats, Number of Rats With Histological
Signs of Stroke, and Brain Weight of Stroke-Prone Rats
in Placebo-Treated and Nimodipine-Treated Groups
No. of Rats Brain Weight, g
Group n With Stroke (mean±SEM)
SP-placebo 7 7 2.54+0.11
SP-nimo 7 2 1.81+0.02*
SP-placebo indicates stroke-prone rats in placebo-treated
group; SP-nimo, stroke-prone rats in nimodipine-treated group.
*P<.0001 (analysis of variance: F1,12=34.403).
found did not differ from the other SP-nimo animals.
Statistical analysis showed that the brain weight in the
SP-placebo group was significantly higher than in the
SP-nimo group (ANOVA: F1,12=34.403, P<.0001).
The cellular distribution and intensity of PKCy im-
munoreactivity (ir) in the dorsal hippocampal CA1 of
SP-nimo animals (Figure, panel A) were similar to that
in normotensive Wistar rats and in mice.15 In short,
moderate levels of PKCy-ir were found in pyramidal
and nonpyramidal cell bodies, and apical dendrites of
the CA1 pyramidal cells were also moderately stained.
In contrast to the SP-nimo group, PKCy-ir in all SP-
placebo rats showed conspicuous alterations. In large
parts of the hippocampus the staining intensity was
prominently increased. A much more dense immuno-
staining was consistently found in the CA1 pyramidal
cell layer. Cell bodies, their apical dendrites in the
stratum radiatum and lacunosum moleculare, and basal
dendrites in the stratum oriens showed an enhanced
PKCy-ir.
In the hippocampal CA1 of SP-nimo rats, the local-
ization of PV-ir (Figure, panel C) closely resembled
earlier descriptions in normotensive rats14'7 and was
found in the nonpyramidal cell type. In the CA1 most
PV-ir was situated in the stratum pyramidale and stra-
tum oriens. The immunoreactive dendrites extended
into the stratum radiatum and stratum oriens and are
characterized by their varicose appearance. The PV-ir
interneurons gave rise to a dense axonal plexus around
the cell bodies and proximal dendrites of the CA1
pyramidal cells. In all SP-placebo animals PV-ir in the
CA1 was considerably lower (Figure, panel D). A
reduced amount of PV-ir in both cell bodies and
dendrites was observed, and the density of the axonal
plexus surrounding CA1 pyramidal cells also declined.
In the two SP-nimo animals that developed a minor
stroke, there were no obvious qualitative alterations in
PV- or PKCy-ir.
Discussion
We examined immunocytochemical alterations in the
hippocampal CA1 after spontaneous strokes by compar-
ing aging nontreated SHR-SP with aging, nimodipine-
treated SHR-SP. Administration of the L-type calcium
channel blocker nimodipine from the age of 46 weeks
prevented the occurrence of strokes in 80% of the
SHR-SP.5 Although signs of a minor stroke were ob-
served in two nimodipine-treated rats, the possibility
that these animals developed cerebrovascular lesions
before the treatment was started cannot be excluded. In
the present study we used nimodipine-treated animals
as nonstroke controls. In addition to its cerebrovascularthe two SP~nimo animals in which signs of stroke were
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Photomicrographs of the distribu-
tion of protein kinase C-y(PKCy)
(A,B) and parvalbumin (PV) (C,D) in
the hippocampal CA1 of control
(right panels) and nimodipine-
treated (left panels) spontaneously
hypertensive stroke-prone rats.
Photographs of both PKCy and PV
are taken from the same animal.
Note that after stroke (control rat)
the immunoreactivity for PKCy in-
creases in pyramidal cell bodies as
well as in apical and basal den-
drites. In the same hippocampal re-
gion the immunoreactivity for PV de-
creases. Fewer labeled dendrites
and interneurons were observed,
and the density of the axosomatic
plexus surrounding CA1 pyramidal
cells was also reduced. or indicates
stratum oriens; rad, stratum radia-
tum; pyr, stratum pyramidale; and
mol, lacunosum moleculare.
mol
actions, nimodipine also directly antagonizes neuronal
calcium influx.18 Recent pilot studies did not reveal
alterations in the expression of PKC-y-ir and PV-ir in
young SHR-SP treated with nimodipine, which supports
the use of SP-nimo animals as nonstroke controls.
In contrast to SP-placebo animals, which all devel-
oped strokes and displayed extreme brain edema, the
two symptomatic SP-nimo animals did not show any
brain tissue swelling. Beneficial effects of nimodipine on
the development of edema after experimentally induced
ischemia have previously been described.19 If the
strokes in the SP-nimo animals did occur after the
treatment was started, nimodipine may have prevented
edema formation after spontaneous strokes.
In experimentally induced cerebral ischemia, the py-
ramidal cells of the hippocampal CA1 are selectively
vulnerable and eventually die.8 Spontaneous strokes did
not yield cellular necrosis in the hippocampal CA1 (data
not shown); however, prominent neurochemical changes
were observed in aging symptomatic SP-placebo rats. In
the dorsal hippocampus, CA1 pyramidal cells showed a
striking increase of PKCy-ir, whereas the PV-ir in inter-
neurons was profoundly reduced after stroke. These
alterations were consistent and did not correlate with the
putative survival time after stroke.
Previously, we showed that PKCy-ir in pyramidal
cells, as visualized with the 36G9 monoclonal antibody,
was enhanced in both cell bodies and dendrites after
electrical stimulation of the amygdala in a kindling
model for epilepsy20 and chemical stimulation with
carbachol and phorbol esters.'52' We therefore inter-
pret neurons with enhanced PKCy-ir as functionally
activated cells.15 Spontaneous cerebrovascular insults
and concomitant edema in aging SP-placebo animals
were shown in the present study to yield a similar
increase in PKCy-ir in pyramidal cells of the dorsal
hippocampal CAl. It has been suggested that PKC
activation and translocation play an important role in
the pathophysiology of ischemic brain injury and brain
edema.10-12 Using biochemical techniques, Olah et a122
previously demonstrated a (long-lasting) increased con-
centration and activity of PKC in the hippocampal CA1
after experimentally induced ischemia in gerbils. More-
over, it was shown that PKC inhibitors can prevent
ischemic neuronal damage in hippocampal CAl neu-
rons.23 The present data indicate that at least the
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spontaneous strokes, which corroborates the observa-
tions of Wieloch et al,24 who showed that an increased
translocation of PKC in the striatum of ischemic rats is
most prominent for the y-isoform.
The increased pyramidal cell activation, as visualized
by an increased PKCy-ir, after spontaneous strokes may
be explained by an increased excitatory input on pyrami-
dal cells, with the neurotransmitter glutamate as the most
likely candidate. Numerous reports demonstrate an in-
creased glutamate release in the hippocampus after
experimentally induced ischemia, which has been associ-
ated with neuronal damage (for review, see Reference 9).
We also observed a clear loss of PV-ir interneurons in
the CA1 after spontaneous strokes. PV is a calcium
binding protein that is present in a subset of hippocam-
pal y-aminobutyric acid (GABA)-ergic inhibitory inter-
neurons innervating the hippocampal pyramidal cells.17
In the hippocampus GABA-mediated inhibition plays
an important role in regulating pyramidal cell activity,25
and recent studies have shown that withdrawal of
GABA resulted in hyperexcitability of CA1 pyramidal
cells.26 Our data suggest that the enhanced pyramidal
cell activity, as indicated by increased PKCy-ir, may
partially be related to a reduced PV/GABAergic inhib-
itory input on these cells. This option is further substan-
tiated by data from Lyden and Hedges,13 who showed
that administration of the GABA agonist muscimol was
equally as protective as the glutamate antagonist MK-
801 in ischemia-induced brain damage. Whether the
reduced amount of PV-ir interneurons after spontane-
ous stroke is related to GABAergic cell loss is under
current investigation.
In summary, the present study shows that the occur-
rence of spontaneous strokes and accompanying edema
formation in aging SHR-SP coincides with consistent
alterations of neuronal functioning in the hippocampal
CAl. The activity of CA1 pyramidal cells is increased,
which may partially be related to a decreased inhibitory
input on these cells. Because CA1 pyramidal cells are
the major output cells of the hippocampus, hyperactiv-
ity of these cells is likely to disturb hippocampus-
mediated functions, such as adequate cognitive perfor-
mance in learning and memory tasks.
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